Chronic myeloid leukaemia (CML) provides an illustrative disease model for both molecular
pathogenesis of cancer and rational drug therapy. Imatinib mesylate (IM), a BCR …

With the progress of chronic myeloid leukemia (CML) therapy, the molecular tools used to
diagnose and monitor patients have become sophisticated. Despite this, a complete …

The well‐established molecular pathogenesis of chronic myelogenous leukemia (CML) and
its consequences for laboratory testing and clinical management illustrate a classic …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

Introduction: Despite the advent of molecular assessment, banding cytogenetics and
fluorescence in situ hybridization (FISH) still have a significant role in diagnostic and …

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …

The reciprocal translocation between chromosomes 9 and 22 [t (9; 22)(q34; q11),
Philadelphia chromosome] creates a BCR-ABL1 fusion protein that occurs in approximately …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

A significant minority of chronic myeloid leukaemia patients eventually develop resistance to
imatinib, often as a result of point mutations within the BCR-ABL kinase domain. Second-line …

The course of chronic myeloid leukemia (CML) and the response to treatment with tyrosine
kinase inhibitors (TKIs) are best monitored and assessed using two molecular tests: the first …